Fingerprint
Dive into the research topics of 'Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): A multicenter, open-label phase 2 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): A multicenter, open-label phase 2 trial
Madan Jagasia, Miguel Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah, Yi Bin Chen, Salman Fazal, Fitzroy W. Dawkins, Michael C. Arbushites, Chuan Tian, Laura Connelly-Smith, Michael D. Howell, H. Jean Khoury
Research output: Contribution to journal › Article › peer-review
96
Scopus
citations